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Abstract: Six N-nitroaryl-2-amino-1,3-dichloropropane derivatives have been prepared and evaluated against 18 
cancer cell lines and two non-cancerous cell lines. Analysis of cell viability data and IC50 values indicated that the 
presence of a trifluoromethyl group in the nitroaryl moiety is an important structural feature associated with the 
compounds’ cytotoxicities.  
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The design, synthesis and therapeutic utility of nitroaromatic pro-drugs has attracted considerable interest and this 
area of medicinal chemistry has been recently reviewed.1 Within this general class of pro-drugs, the nitrogen-
mustards of general structure 1 have received particular attention as potential anti-cancer agents (Scheme 1).2,3 In 
these compounds, the bioreduction of an appropriately positioned ortho- or para-nitro group produces the 
corresponding hydroxylamine/amine derivative 2 with a concomitant augmentation of the nucleophilic character of 
the mustard’s nitrogen atom. An intramolecular nucleophilic substitution reaction subsequently follows producing a 
highly reactive aziridinium ion 3 which is believed to be responsible for DNA alkylation. The remaining chloroethyl 




Scheme 1. Nitroaromatic pro-drugs acting as anti-cancer agents. 
 
Compounds of general structure 4 appear to be under-represented in the literature and a similar mode of DNA 
alkylation might be feasible for these compounds via the hydroxylamine/amine 5 and the aziridinium ion 6 (Scheme 
1). In view of the extensive interest in fluorinated drugs,4-7 and our work in this area,8 we were particularly interested 
in evaluating the anti-cancer properties of trifluoromethylated nitroaromatics and hence compounds 10d-f were 
chosen as target molecules (Scheme 2). One potential benefit of the secondary amine group in compounds 10d-f is 
the opportunity for the >NH group to participate in intramolecular hydrogen bonding with either an appositely 
located ortho-nitro or -trifluoromethyl group. The mono-nitro derivatives 10a and 10b were chosen as reference 
compounds and compound 10c was also included in this study because the 2,4-di-nitro structural motif is a common 
feature of many known pro-drugs of general structure 1.3 The series of nitroaromatic compounds 10a-f were 
prepared from their diol precursors 9a-f respectively which in turn were synthesised from an appropriately 




Scheme 2. Reagents and conditions: (i) K2CO3, DMSO, heat 70-80 oC, 3 h; (ii) (a) MeSO2Cl, Et3N, rt, (b) LiCl, DMF, heat 
70 oC, 2 h.  
 
The cell viabilities (Table 1) and the IC50 values (Table 2) relating to a selection of 18 cancer cell lines and 2 non-
cancerous cell lines were determined in the presence of the diols 9a-f and the dichloro compounds 10a-f. The ratio 
of the percentage cell viability 9 / percentage cell viability 10 is also reported in Table 1 as an indication of the 

























































































































































































































































































































































































































































































































































































































































































































































































































































































Table 1. Cell viabilities (%) of diols 9a-f and dichlorides 10a-f (all at 100 µM). Results are expressed as the average 
percentage of cell viability ± standard deviation from three independent experiments. 
 
Examination of Table 1 reveals that in the majority of entries, the cell viabilities of the diols 9a-f exceeds that of the 
corresponding dichloro derivatives 10a-f and hence the ratio is greater than 1. This demonstrates that the presence 
of the mustard moiety is efficacious in reducing the cell viabilities in comparison to the diol substituents. The 
magnitude of this ratio is generally low (between 1 and 2) for the majority of the non-trifluoromethylated series of 
compounds whereas the trifluoromethylated compounds exhibit significantly larger values across the majority of cell 
lines. The pair of trifluoromethylated compounds 9e/10e exhibit the highest ratios in 13 of the 20 cell lines. 
 
With the exception of the breast cancer MDA-MB-468 and the lung cell MRC5 cell lines, all of the other cell lines 
have their three lowest cell viabilities associated with the three trifluoromethylated compounds 10d-10f. The 
magnitude of the difference between the cell viabilities of the trifluoromethylated and non-trifluoromethylated 
compounds is noteworthy; for example for the lung cancer A549 cell line the cell viabilities recorded for the 
trifluoromethylated derivatives 10d-10f (24.6-37.1%) are lower than those displayed by the non-trifluoromethylated 
compounds 10a-10c (59.4-82.9%). It is also evident from the data in Table 1 that some dichloro-compounds exhibit 
enhanced cytotoxicity towards the non-cancerous lung cell line MRC5. For example, in the presence of compounds 
10d and 10e, 13 of the 18 cancerous cell lines are associated with higher cell viabilities compared to the MRC5 cell 
line. 
 
Inspection of the IC50 data presented in Table 2 indicates that the majority of the IC50 values associated with the diols 
9a-9f are greater than 100 µM regardless of the presence/absence of a trifluoromethyl group in the aryl ring. Only 
the diols 9b (MRC5 cell line), 9e (MCF7 cell line) and 9f (MCF7 and MRC5 cell lines) showed values less than 100 µM. 
Within the non-trifluoromethylated series of dichloro-compounds 10a-10c, only six IC50 values below 100 µM are 
observed; these are associated with the MCF7 cell line (all three compounds), the MRC5 cell line (compounds 10b 
and 10c) and the T47D cell line (compound 10c only). In contrast, the trifluoromethylated derivatives 10d-10f exhibit 
IC50 values below 100 µM for the majority of the entries in Table 2 (14, 18 and 12 entries for each compound 
respectively) thus supporting the hypothesis that the trifluoromethyl group is an important factor associated with 
the cytotoxicity of these compounds. Compound 10e displayed the lowest IC50 values and is the only compound 
associated with IC50 values below 20 µM in 3 cell-lines [MCF7 (12.1 µM), Caco2 (10.1 µM) and CNE1 (15.3 µM)]. 
 
It is also evident from the data in Table 2 that the five derivatives 10b-f are cytotoxic towards the non-cancerous 
lung cell line MRC5 with IC50 values within the range 31.0-62.1 µM. The only compound to show an IC50 value under 
100 µM against the other non-cancerous cell line studied (the MCF10A breast cell line) was the trifluoromethylated 
derivative 10e (81 µM). 
 
Cancer type Cell 
line 
9a 10a 9b 10b 9c 10c 9d 10d 9e 10e 9f 10f 













































>100 >100 52.1 ± 
5.1 
>100 >100 
Breast Cancer SKBR3 >10
0 






>100 >100 >100 >100 
Breast Cancer T47D >10
0 
>100 >100 >100 >10
0 






>100 34.7 ± 
1.2 
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1.8 














>100 33.1 ± 
8.1 












>100 92.1 ± 
2.1 












>100 33.4 ± 
4.5 
>100 43.4 ± 
4.9 
Lung Cancer A549 >10
0 






>100 57.7 ± 
1.7 
>100 70.4 ± 
1.1 
Lung Cancer H1299 >10
0 

















>100 15.3 ± 
1.9 





















>100 55.1 ± 
2.5 












>100 33.7 ± 
2.7 




































>100 33.3 ± 
2.5 








































Table 2. IC50 values (µM) of diols 9a-f and dichlorides 10a-f. Results are expressed as the average IC50 value  
± standard deviation from three independent experiments. 
 
A commonly accepted mode of action of nitroaromatic pro-drugs is through bioreduction of a nitro group leading to 
highly reactive aziridinium ions as already illustrated in Scheme 1. A possible explanation of the mode of action of 
the trifluoromethylated compounds 10d-f is that bioreduction of the nitro group in these compounds (eg compound 
10e, Scheme 3) would give the amine (or hydroxylamine) derivative 11 from which HF may be evolved resulting in 
the production of the difluoro derivative 12 as a potential alkylating agent.9 The presence of the 1,3-dichloroproane 
moiety is important for biological activity suggesting that this group could also be a potential alkylating agent. 
Compounds 10a-f may have the potential to act as alkylating reagents (rather than pro-drugs) without the prior 
reduction of a nitro group; our previously work demonstrated that compound 13 can be transformed into compound 
15 presumably via an intermediate aziridinium ion 14 (Scheme 3).10 However, this potential mode of alkylation 
would not account for the clear differences in biological activity shown between the non-trifluoromethylated 




Scheme 3. Potential modes of DNA alkylation. 
 
In conclusion, we have demonstrated that the elevated cytotoxicities of compounds 10d-f compared to compounds 
10a-c can be attributed to the presence of a trifluoromethyl group. Of the three trifluoromethylated compounds 
evaluated, compound 10e appears to be the most cytotoxic to the majority of cell lines but it is also cytotoxic to non-
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